Травматология и ортопедия России. 2011; : 138-143
ОСОБЕННОСТИ ВЫБОРА АНТИКОАГУЛЯНТОВ ДЛЯ ПРОФИЛАКТИКИ ВЕНОЗНЫХ ТРОМБОЗОВ И ЭМБОЛИЙ ПОСЛЕ КРУПНЫХ ОРТОПЕДИЧЕСКИХ ОПЕРАЦИЙ: ВЗГЛЯД КЛИНИЧЕСКОГО ФАРМАКОЛОГА
https://doi.org/10.21823/2311-2905-2011-0-1-138-143Аннотация
Проблема развития венозных тромбозов и эмболий (ВТЭ) до настоящего времени остается серьезной проблемой в области травматологии и ортопедии. Для сохранения равновесия между эффективностью тромбопрофилактики и риском серьезных кровотечений у особых групп пациентов предлагается проводить выбор конкретного антикоагулянта на индивидуальной основе с учетом массы тела пациента, функции его печени и почек, длительности курса профилактики, возможность проведения лабораторного мониторирования показателей свертываемости крови после выписки из стационара. Анализируется возможность использования новых пероральных антикоагулянтов у пациентов после эндопротезирования тазобедренного или коленного сустава.
Список литературы
1. Протокол ведения больных. Профилактика тромбоэмболии легочной артерии при хирургических и иных инвазивных вмешательствах (ОСТ 91500.11.0007-2003). – М. : НЬЮДИАМЕД, 2004. – 64 с.
2. Российские клинические рекомендации по диагностике, лечению и профилактике венозных тромбоэмболических осложнений // Флебология. – 2010. – №1, вып. 2. – С. 3–37.
3. Camporese, G. Low-molecular-weight heparin versus compression stockings for thromboprophylaxis after knee arthroscopy: a randomized trial / G. Camporese [et al.] // Ann. Intern. Med. – 2008. – Vol. 149, N 2. – P.73–82.
4. Dahl, O.E. Efficacy and safety profile of dabigatran etexilate compared with enoxaparin in primary venous thromboembolism prevention after total knee or hip replacement surgery in patients over 75 years / O.E. Dahl [et al.] // Blood. – 2008. – Vol. 112. – P. 167
5. Dahl, O.E. Efficacy and safety profile of dabigatran etexilate for the prevention of venous thromboembolism in moderately renally impaired patients after total knee or hip replacement surgery / O.E. Dahl [et al.] // Blood. – 2008. – Vol. 112. – P. 361.
6. Geerts, W.H. Prevention of venous thromboembolism: the Seventh ACCP Conference on Antithrombotic and Thrombolytic Therapy / W.H. Geerts [et al.] // Chest. – 2004. – Vol. 126. – Р. 338–400.
7. Geerts, W.H. Prevention of venous thromboembolism: Evidence-Based Clinical Practice Guidelines (8th ed.) / W.H. Geerts [et al.] // Chest. – 2008. –Vol. 133. – Р. 381–453.
8. Hill, J. Reducing the risk of venous thromboembolism in patients admitted to hospital: summary of the NICE guideline / J. Hill, T. Treasure // Heart. 2010. – Vol. 96, N 11. – P. 879–882.
9. Huisman, M.V. Enoxaparin versus dabigatran or rivaroxaban for thromboprophylaxis after hip or knee arthroplasty results of separate pooled analyses of phase III multicenter randomized trials / M.V. Huisman, D. J. Quinlan, O. E. Dahl, S. Schulman // Cardiovasc. Qual. Outcomes. – 2010. – Vol. 3, N 6. – P. 652–660.
10. Kujath, P. Incidence and prophylaxis of deep venous thrombosis in outpatients with injury of the lower limb/ P. Kujath, U. Spannagel, W. Habscheid // Haemostasis. – 1993. – Vol. 23, Suppl. 1. – P. 20–26.
11. Kock, H.J. Thromboprophylaxis with low-molecularweight heparin in outpatients with plaster-cast immobilisation of the leg / H.J. Kock [et al.] // Lancet. – 1995. – N 346. – P.459–461
12. Koch, A. Low molecular weight heparin and unfractionated heparin in thrombosis prophylaxis: meta-analysis based on original patient data / A. Koch, S. Ziegler, H. Breitschwerdt, N. Victor // Thromb. Res. – 2001. – Vol. 102. – P. 295 –309.
13. Nurmohamed, M.T. Low-molecular-weight heparin versus standard heparin in general and orthopaedic surgery: a meta-analysis / M.T. Nurmohamed [et al.] // Lancet. – 1992. – Vol. 340. – Р. 152–156.
14. Samama, C.M. Epidemiology of venous thromboembolism after lower limb arthroplasty: the FOTO study / C.M. Samama [et al.] // J. Thromb. Haemost. 2007. – Vol. 5, N 12. – P.2360 –2367.
15. Selby, R. A prospective cohort study of the epidemiology of symptomatic thromboembolism (VTE) after isolated leg fractures distal to the knee without thromboprophylaxis / R. Selby [et al.] // Blood. – 2005. – Vol. 106. – P. 583.
16. Schmida, P. Low-molecular-weight heparin in patients with renal insufficiency / P. Schmida, A. G. Fischerb, W. A. Wuillemina // Swiss. Med. Weekly. – 2009. – Vol. 139, N 31-32. – P. 438–452.
17. Strebel, N. Preoperative or postoperative start of prophylaxis for venous thromboembolism with lowmolecular-weight heparin in elective hip surgery? / N. Strebel [et al.] // Arch. Intern. Med. – 2002. – Vol. 162. – P.1451–1456.
18. Warwick, D. Insufficient duration of venous thromboembolism prophylaxis after total hip or knee replacement when compared with the time course of thromboembolic events: findings from the Global Orthopaedic Registry / D. Warwick [et al.] / J. Bone Joint. Surg. – 2007. – Vol. 89-B. – Р. 799 –807.
19. Wirth, T. Prevention of venous thromboembolism after knee arthroscopy with low-molecular weight heparin (reviparin): results of a randomized controlled trial / T. Wirth [et al.] // Arthroscopy. – 2001. – Vol. 17. – P. 393–399.
Traumatology and Orthopedics of Russia. 2011; : 138-143
SPECIFICITY OF ANTICOAGULANT CHOICE FOR VTE PROPHYLAXES AFTER MAJOR ORTHOPEDIC SURGERY- THE VIEW OF CLINICAL PHARMACOLOGISTS
https://doi.org/10.21823/2311-2905-2011-0-1-138-143Abstract
The issue of development of venous thrombosis and embolism still remains a serious problem in the traumatology and orthopedics. To maintain a balance between efficacy of thromboprophylaxis and the risk of serious bleeding in special patient groups the authors encourage to undertake the choice of anticoagulant on an individual basis taking into account the patient's weight, as his liver and kidneys, the duration of prophylaxis course, the possibility of laboratory monitoring of coagulation parameters after discharge from hospital. The authors analyze the possibility of the use of new oral anticoagulants in patients after hip or knee arthroplasty.
References
1. Protokol vedeniya bol'nykh. Profilaktika tromboembolii legochnoi arterii pri khirurgicheskikh i inykh invazivnykh vmeshatel'stvakh (OST 91500.11.0007-2003). – M. : N''YuDIAMED, 2004. – 64 s.
2. Rossiiskie klinicheskie rekomendatsii po diagnostike, lecheniyu i profilaktike venoznykh tromboembolicheskikh oslozhnenii // Flebologiya. – 2010. – №1, vyp. 2. – S. 3–37.
3. Camporese, G. Low-molecular-weight heparin versus compression stockings for thromboprophylaxis after knee arthroscopy: a randomized trial / G. Camporese [et al.] // Ann. Intern. Med. – 2008. – Vol. 149, N 2. – P.73–82.
4. Dahl, O.E. Efficacy and safety profile of dabigatran etexilate compared with enoxaparin in primary venous thromboembolism prevention after total knee or hip replacement surgery in patients over 75 years / O.E. Dahl [et al.] // Blood. – 2008. – Vol. 112. – P. 167
5. Dahl, O.E. Efficacy and safety profile of dabigatran etexilate for the prevention of venous thromboembolism in moderately renally impaired patients after total knee or hip replacement surgery / O.E. Dahl [et al.] // Blood. – 2008. – Vol. 112. – P. 361.
6. Geerts, W.H. Prevention of venous thromboembolism: the Seventh ACCP Conference on Antithrombotic and Thrombolytic Therapy / W.H. Geerts [et al.] // Chest. – 2004. – Vol. 126. – R. 338–400.
7. Geerts, W.H. Prevention of venous thromboembolism: Evidence-Based Clinical Practice Guidelines (8th ed.) / W.H. Geerts [et al.] // Chest. – 2008. –Vol. 133. – R. 381–453.
8. Hill, J. Reducing the risk of venous thromboembolism in patients admitted to hospital: summary of the NICE guideline / J. Hill, T. Treasure // Heart. 2010. – Vol. 96, N 11. – P. 879–882.
9. Huisman, M.V. Enoxaparin versus dabigatran or rivaroxaban for thromboprophylaxis after hip or knee arthroplasty results of separate pooled analyses of phase III multicenter randomized trials / M.V. Huisman, D. J. Quinlan, O. E. Dahl, S. Schulman // Cardiovasc. Qual. Outcomes. – 2010. – Vol. 3, N 6. – P. 652–660.
10. Kujath, P. Incidence and prophylaxis of deep venous thrombosis in outpatients with injury of the lower limb/ P. Kujath, U. Spannagel, W. Habscheid // Haemostasis. – 1993. – Vol. 23, Suppl. 1. – P. 20–26.
11. Kock, H.J. Thromboprophylaxis with low-molecularweight heparin in outpatients with plaster-cast immobilisation of the leg / H.J. Kock [et al.] // Lancet. – 1995. – N 346. – P.459–461
12. Koch, A. Low molecular weight heparin and unfractionated heparin in thrombosis prophylaxis: meta-analysis based on original patient data / A. Koch, S. Ziegler, H. Breitschwerdt, N. Victor // Thromb. Res. – 2001. – Vol. 102. – P. 295 –309.
13. Nurmohamed, M.T. Low-molecular-weight heparin versus standard heparin in general and orthopaedic surgery: a meta-analysis / M.T. Nurmohamed [et al.] // Lancet. – 1992. – Vol. 340. – R. 152–156.
14. Samama, C.M. Epidemiology of venous thromboembolism after lower limb arthroplasty: the FOTO study / C.M. Samama [et al.] // J. Thromb. Haemost. 2007. – Vol. 5, N 12. – P.2360 –2367.
15. Selby, R. A prospective cohort study of the epidemiology of symptomatic thromboembolism (VTE) after isolated leg fractures distal to the knee without thromboprophylaxis / R. Selby [et al.] // Blood. – 2005. – Vol. 106. – P. 583.
16. Schmida, P. Low-molecular-weight heparin in patients with renal insufficiency / P. Schmida, A. G. Fischerb, W. A. Wuillemina // Swiss. Med. Weekly. – 2009. – Vol. 139, N 31-32. – P. 438–452.
17. Strebel, N. Preoperative or postoperative start of prophylaxis for venous thromboembolism with lowmolecular-weight heparin in elective hip surgery? / N. Strebel [et al.] // Arch. Intern. Med. – 2002. – Vol. 162. – P.1451–1456.
18. Warwick, D. Insufficient duration of venous thromboembolism prophylaxis after total hip or knee replacement when compared with the time course of thromboembolic events: findings from the Global Orthopaedic Registry / D. Warwick [et al.] / J. Bone Joint. Surg. – 2007. – Vol. 89-B. – R. 799 –807.
19. Wirth, T. Prevention of venous thromboembolism after knee arthroscopy with low-molecular weight heparin (reviparin): results of a randomized controlled trial / T. Wirth [et al.] // Arthroscopy. – 2001. – Vol. 17. – P. 393–399.
